N C Daw

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study
    Monika L Metzger
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 25:3130-6. 2007
  2. ncbi Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report
    N C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis, College of Medicine, Memphis, Tennessee, USA
    Pediatr Hematol Oncol 18:123-8. 2001
  3. ncbi Case reports: polymethylmethacrylate lung embolus after limb-salvage surgery of the distal femur
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Orthop Relat Res 448:252-6. 2006
  4. ncbi Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
  5. ncbi Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:829-37. 2004
  6. pmc Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour
    Najat C Daw
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Eur J Cancer 45:99-106. 2009
  7. ncbi Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children's Research Hospital experience
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 97:2839-47. 2003
  8. ncbi Metastatic osteosarcoma
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee 38105 2794, USA
    Cancer 106:403-12. 2006
  9. ncbi Patterns of abdominal relapse and role of sonography in Wilms tumor
    Najat C Daw
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Hematol Oncol 19:107-15. 2002
  10. ncbi Tumor recurrence at thoracostomy tube insertion sites: a report of two pediatric cases
    Andrea A Hayes-Jordan
    Department of Surgery, Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Surg 39:1565-7. 2004

Detail Information

Publications48

  1. ncbi Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study
    Monika L Metzger
    St Jude Children s Research Hospital, Memphis, TN, USA
    J Clin Oncol 25:3130-6. 2007
    ..A phase II study was conducted to evaluate the activity and safety of topotecan in pediatric patients with recurrent Wilms' tumor...
  2. ncbi Metastatic osteosarcoma to the liver after treatment for synovial sarcoma: a case report
    N C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, and the University of Tennessee, Memphis, College of Medicine, Memphis, Tennessee, USA
    Pediatr Hematol Oncol 18:123-8. 2001
    ..The risk of radiation-induced osteosarcoma should always be considered in decisions about treatment for soft-tissue sarcoma...
  3. ncbi Case reports: polymethylmethacrylate lung embolus after limb-salvage surgery of the distal femur
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Clin Orthop Relat Res 448:252-6. 2006
    ..Awareness of this potential complication should prompt investigation of possible pulmonary embolism and may prevent unnecessary thoracotomy...
  4. ncbi Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
    ..Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors...
  5. ncbi Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 22:829-37. 2004
    ..We conducted a phase I trial of the injectable formulation of topotecan given orally once daily for 5 days for 2 consecutive weeks (qd x 5 x 2) in pediatric patients with refractory solid tumors...
  6. pmc Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour
    Najat C Daw
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Eur J Cancer 45:99-106. 2009
    ..Treatment with ICE, nephrectomy and radiotherapy significantly reduces GFR, largely as the result of nephrectomy. Adjustment of carboplatin dosage on the basis of GFR and careful monitoring of renal function may alleviate nephrotoxicity...
  7. ncbi Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children's Research Hospital experience
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 97:2839-47. 2003
    ..In the current study, the authors reviewed their institutional experience with these tumors to characterize their clinical features in pediatric patients and assess the impact of surgical resection on outcome...
  8. ncbi Metastatic osteosarcoma
    Najat C Daw
    Department of Hematology Oncology, St Jude Children s Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee 38105 2794, USA
    Cancer 106:403-12. 2006
    ..The initial study (OS-86) used ifosfamide, cisplatin, doxorubicin, and high-dose methotrexate, and the subsequent study (OS-91) used the same agents at similar doses, but carboplatin was substituted for cisplatin...
  9. ncbi Patterns of abdominal relapse and role of sonography in Wilms tumor
    Najat C Daw
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Hematol Oncol 19:107-15. 2002
    ..The results suggest that regular sonographic surveillance for 3 years after therapy is likely to reveal most abdominal recurrences. Supplementation with CT or MR imaging is indicated for detection of nephrogenic rests...
  10. ncbi Tumor recurrence at thoracostomy tube insertion sites: a report of two pediatric cases
    Andrea A Hayes-Jordan
    Department of Surgery, Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Surg 39:1565-7. 2004
    ....
  11. ncbi Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma
    C Rodriguez-Galindo
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Med Pediatr Oncol 36:605-11. 2001
    ....
  12. ncbi Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794l, USA
    J Clin Oncol 24:563-70. 2006
    ....
  13. ncbi Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients
    Burgess B Freeman
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer Invest 24:310-7. 2006
    ..Finally, the future for the use of gefitinib in pediatrics is similar to that of other molecularly targeted agents and awaits definition of tumors and patient populations in which it will be most advantageous...
  14. ncbi Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid tumors
    M Beth McCarville
    Department of Radiological Sciences, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105 2794, USA
    Radiology 239:514-20. 2006
    ..To retrospectively assess whether computed tomographic (CT) findings can indicate the benign or malignant nature of pulmonary nodules in pediatric patients with malignant solid primary tumors...
  15. ncbi The cause and clinical significance of central tumor photopenia on thallium scintigraphy of pediatric osteosarcoma of the extremity
    M Beth McCarville
    Department of Radiological Sciences, Division of Diagnostic Imaging, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105 2974, USA
    AJR Am J Roentgenol 188:572-8. 2007
    ....
  16. ncbi Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies
    Carlos Rodriguez-Galindo
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 110:375-84. 2007
    ..As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups...
  17. ncbi Transfer of complex frontline anticancer therapy to a developing country: the St. Jude osteosarcoma experience in Chile
    Gaston K Rivera
    International Outreach Program, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:1143-6. 2008
    ..Jude Children's Research Hospital (sponsor) and Calvo Mackenna Hospital (CMH, partner), a public pediatric hospital and national center for the treatment of bone tumors in Santiago, Chile...
  18. doi Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma
    Fariba Navid
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 113:419-25. 2008
    ..The combination of gemcitabine and docetaxel has demonstrated promise in sarcomas diagnosed in adults. In the current study, the toxicity and efficacy of this combination were evaluated in pediatric sarcomas...
  19. pmc Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia
    Pamela S Hinds
    Division of Nursing Research, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Eur J Oncol Nurs 13:156-63. 2009
    ..Our findings demonstrates the feasibility of measuring HRQoL in adolescents with OS or AML (and their parents) at the time of diagnosis, and thus their HRQoL ratings can be used to inform their cancer care from diagnosis forward...
  20. pmc Late effects of treatment for wilms tumor
    Karen D Wright
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Pediatr Hematol Oncol 26:407-13. 2009
    ..Careful medical and epidemiological monitoring of survivors can provide critical information to further optimize therapy while minimizing long-term sequelae...
  21. pmc Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors
    Wayne L Furman
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 3678, USA
    J Clin Oncol 27:4599-604. 2009
    ..To assess the effect of gefitinib on the pharmacokinetics of IV irinotecan and on the bioavailability of a single oral dose of irinotecan...
  22. doi Estimation of potential excess cancer incidence in pediatric 201Tl imaging
    Sue C Kaste
    Department of Radiological Sciences, St Jude Children s Research Hospital, and Department of Radiology, College of Medicine, University of Tennessee School of Health Science Center, 262 Danny Thomas Place, Mailstop 220, Memphis, TN 38105, USA
    AJR Am J Roentgenol 194:245-9. 2010
    ..The purpose of our study was to estimate the potential excess lifetime cancer incidence and mortality associated with thallium bone imaging in pediatric patients...
  23. ncbi Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features
    Sue C Kaste
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 47:152-62. 2006
    ..Osteosarcoma (OS) arising from the surface of bone is far less common than its intramedullary counterpart. Although surface OSs share some radiographic and clinical features, they can be divided into three distinct histologic subtypes...
  24. ncbi High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Judes Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 100:1724-33. 2004
    ..The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome...
  25. ncbi Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide
    Carlos Rodriguez-Galindo
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Pediatr Hematol Oncol 24:250-5. 2002
    ..By identifying new chemotherapeutic strategies, the outcome of these patients can be improved and the toxicity of treatment regimens decreased...
  26. ncbi Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000)
    Carlos Rodriguez-Galindo
    Department of Hematology Oncology, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee, Memphis, USA
    Cancer 100:1928-35. 2004
    ..Despite improvements in therapy for osteosarcoma, approximately 4-10% of patients experience a local recurrence and have a poor prognosis...
  27. ncbi Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors
    Carlos Rodriguez-Galindo
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2795, USA
    Cancer Chemother Pharmacol 57:15-24. 2006
    ..Combining both agents may increase the amount of camptothecin delivered to the tumor, without additive toxicity...
  28. ncbi Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital
    Jeffrey S Dome
    Department of Hematology Oncology St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Pediatr Hematol Oncol 24:192-8. 2002
    ..Because published survival data are more than a decade old and do not reflect advances in therapy, the authors reviewed their experience in treating recurrent Wilms tumor to determine whether the probability of survival has increased...
  29. ncbi Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer
    H Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Ann Oncol 19:178-84. 2008
    ..Little information is available about the diagnosis and management of acute methotrexate (MTX)-induced encephalopathy...
  30. ncbi Osteosarcoma among children aged 5 years or younger: the St. Jude Children's Research Hospital experience
    Christine M Hartford
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Pediatr Hematol Oncol 28:43-7. 2006
    ..These findings and a review of the similar cases in the literature suggest that osteosarcoma's clinical characteristics are similar among young children and older children...
  31. ncbi Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Pediatr Blood Cancer 49:352-7. 2007
    ..Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value...
  32. ncbi Infections in children and young adults with bone malignancies undergoing limb-sparing surgery
    Aditya H Gaur
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA
    Cancer 104:602-10. 2005
    ..The epidemiology, risk factors, and efficacy of therapy for infections complicating limb-sparing surgery (LSS) are not understood completely...
  33. pmc Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors
    Serena S Freeman
    Department of Pathology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 113:1453-61. 2008
    ..In this study, the authors further analyzed the genomic features of EGFR in osteosarcoma tumors and investigated whether they correlate with phosphatase and tensin homolog (PTEN) expression and copy number status...
  34. ncbi Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma
    Kristine R Crews
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    J Pediatr Hematol Oncol 26:764-7. 2004
    ..The reduced area under the curve to the active metabolite SN-38 during ifosfamide therapy predicts a compromised efficacy of irinotecan in this combination...
  35. ncbi Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience
    Aaron Weiss
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 109:1627-37. 2007
    ..Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma (OS). The authors reviewed their experience with TOS to characterize its histologic, radiologic, and clinical features...
  36. ncbi Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity
    Sue C Kaste
    Department of Radiological Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 43:723-8. 2004
    ..We investigated the predictive value of MR imaging-based measures of absolute and relative tumor size and volume at the time of diagnosis. We also assessed the relation of tumor size to age and histologic response...
  37. ncbi Telomerase expression predicts unfavorable outcome in osteosarcoma
    Robert P Sanders
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 22:3790-7. 2004
    ..Laboratory studies suggest that compared with ALT, telomerase expression is associated with increased tumor aggressiveness. We evaluated the clinical significance of telomerase expression in human osteosarcoma...
  38. doi Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma
    Michael J Absalon
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 50:1147-53. 2008
    ..Recent technical advances in CT imaging and data processing have improved the ability to detect small pulmonary nodules in children with bone and soft-tissue sarcoma undergoing radiologic imaging of the chest...
  39. ncbi Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children
    P Kellie Turner
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer Chemother Pharmacol 57:475-82. 2006
    ..To develop and validate a pharmacokinetic limited sampling model (LSM) for intravenous and oral topotecan pharmacokinetic studies in children...
  40. doi FDG positron emission tomography/computed tomography studies of Wilms' tumor
    A K M Moinul Hossain
    Nuclear Imaging Division, Department of Radiological Sciences, MS 220, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    Eur J Nucl Med Mol Imaging 37:1300-8. 2010
    ..The purpose of this analysis was to evaluate the utility of FDG PET/CT scanning in patients with Wilms' tumors...
  41. ncbi A schedule of recombinant Mpl ligand highly effective at preventing lethal myelosuppression in mice given carboplatin and radiation
    B A Abushullaih
    Division of Experimental Hematology, St. Jude Children's Research Hospital, Memphis, Tenn, USA
    Exp Hematol 29:1425-31. 2001
    ....
  42. pmc A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors
    Fredric A Hoffer
    Department of Radiological Sciences, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA
    Cancer 115:1328-37. 2009
    ..This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors...
  43. ncbi Adenocarcinoma of the cervix and vagina in pediatric patients
    Rene Y McNall
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 43:289-94. 2004
    ..The association between tumor excision and excellent outcome suggests that radical hysterectomy or pelvic exenteration is unnecessary. Radiotherapy as an adjunct may have contributed to this outcome...
  44. ncbi Pediatric gastrointestinal stromal tumors and leiomyosarcoma
    Monica S Cypriano
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    Cancer 101:39-50. 2004
    ..The authors sought to characterize the clinicopathologic features of these tumors in pediatric patients...
  45. ncbi PET/CT in the evaluation of childhood sarcomas
    M Beth McCarville
    Department of Radiological Sciences, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    AJR Am J Roentgenol 184:1293-304. 2005
    ..It was useful in monitoring response to chemotherapy, radiation therapy, and radiofrequency ablation and aided the postoperative evaluation of tumor resection sites...
  46. ncbi Osteosarcoma of the pelvis in children and young adults: the St. Jude Children's Research Hospital experience
    Raya Saab
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 103:1468-74. 2005
    ..Pelvic osteosarcomas are difficult to resect. The authors reviewed their institution's experience with patients who had such tumors to characterize the patients' clinical findings and to assess the impact of surgical resection on outcome...
  47. pmc Cephalosporin-resistant pneumococci and sickle cell disease
    Martha L Miller
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Emerg Infect Dis 11:1192-6. 2005
    ..High-level cephalosporin resistance exists in more settings than initially recognized, and its high prevalence in sickle cell disease patients may decrease the efficacy of third-generation cephalosporins in invasive pneumococcal disease...
  48. ncbi Giant cell tumor of bone with pulmonary metastases
    Yasuhiro Okamoto
    Med Pediatr Oncol 41:454-9. 2003